Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07672782 · ClinicalTrials.gov registry record · Phase 2
Tisotumab Vedotin in Squamous Cell Carcinoma of the Vulva
A Phase 2 study, sponsored by GOG Foundation.
- Not yet
- Registry status
- Phase 2
- Development phase
- 28
- Enrollment target
NCT07672782 is a Phase 2 study that has not yet begun recruiting, run by GOG Foundation. The registered enrollment target is 28 participants.
The verdict
NCT07672782, a Phase 2 study, has not yet begun recruiting, sponsored by GOG Foundation.
- NOT YET RECRUITING
- Registry status
- Phase 2
- Development phase
- 28 participants
- Enrollment target
Study Summary
This is an open-label, single arm, phase 2 study designed to evaluate the efficacy of tisotumab vedotin in participants with recurrent or metastatic squamous cell carcinoma of the vulva by estimating the objective response rate. Patients will receive tisotumab vedotin every 3 weeks (21 days plus or minus 3 days). Treatment will continue until either unacceptable toxicity, progression of disease, or investigator/patient request for withdrawal.
Interventions
- DRUG Tisotumab Vedotin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 28 participants |
| Start Date | 2026-11 |
| Est. Completion | 2029-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07672782
The ClinicalTrials.gov registry entry for NCT07672782 describes a study currently listed as not yet recruiting, categorized as Phase 2. The registered enrollment target is 28 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is GOG Foundation, which has 14 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Tisotumab Vedotin is the first listed.
NCT07672782 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07672782 about?
NCT07672782 is a clinical study titled "Tisotumab Vedotin in Squamous Cell Carcinoma of the Vulva". This is an open-label, single arm, phase 2 study designed to evaluate the efficacy of tisotumab vedotin in participants with recurrent or metastatic squamous cell carcinoma of the vulva by estimating the objective response rate. Patients will receive tisotumab vedotin every 3 weeks (21 days plus or...
What is the current status of trial NCT07672782?
This trial is currently not yet recruiting. It is a Phase 2 study. The enrollment target is 28 participants. The study started on 2026-11. Estimated completion is 2029-12.
What interventions are being tested in trial NCT07672782?
The interventions under investigation include: Tisotumab Vedotin (DRUG).
Who is sponsoring clinical trial NCT07672782?
This trial is sponsored by GOG Foundation, which has 14 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.